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Abstract 
Although TNF plays an important role in several physiological and pathological conditions, the hallmark of this important cytokine has been its 
selective cytotoxic activity on tumor cells. Since its cloning in 1984, understanding of how TNF selectively kills tumor cells has been the subject of 
research in many laboratories. Here we review TNF-induced post-receptor signaling mechanisms which seem to be involved in the pathway to 
cytotoxicity. 
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1. Introduction 
TNF is a cytokine which is mainly produced by acti- 
vated macrophages, although several other cell types can 
produce small amounts (reviewed in [l-3]). The original 
interest in TNF was based on its antitumoral activity [4]. 
After cloning of the gene and purification of the recom- 
binant protein, it soon became clear that TNF also exerts 
biological effects on different normal cell types. This 
implicates an important role for TNF in several physio- 
logical and pathological conditions, for example as a 
crucial mediator in septic shock and cerebral malaria 
(reviewed in [3,5,6]). Although host-mediated effects, i.e. 
actions of TNF on normal cells, are certainly also in- 
volved in the antitumoral activity of TNF in vivo, the 
direct cytotoxic activity of TNF on many types of malig- 
nant cells has been studied most extensively. The thera- 
peutic value of TNF in the treatment of cancer is limited 
by toxic side effects occurring at high TNF doses, and 
by a wide variation in TNF sensitivity of tumor cells. 
Indeed, on some tumor cells TNF at most exerts a ‘cyto- 
static’ activity, while some other tumor cells do not re- 
spond to TNF at all. The TNF sensitivity of tumor cells 
is not correlated with the type or the histological origin 
of the cells. As a rule, untransformed cell lines are resis- 
tant to the cytotoxic effect of TNF, although embryonal 
fibroblastic cells may be an exception [7]. A large number 
of tumor cells which are resistant to TNF as such, do 
become sensitive when TNF is used in combination with 
interferon-y or some chemotherapeutic agents [g-lo]. 
However, such combination treatments may also result 
in an enhanced toxicity for the host [l I]. Understanding 
of the signaling pathways leading to TNF cytotoxicity in 
vitro can greatly contribute to our search for strategies 
to improve the therapeutic value of TNF. Results may 
benefit the development of combination treatments with 
an improved therapeutic index, and may also contribute 
to the development of agents liable to mimic the cyto- 
toxic activity of TNF, but in a more selective manner. 
In this overview we discuss the signaling mechanisms 
which presumably lead to TNF cytotoxicity in vitro. We 
will mainly focus on results which have been obtained in 
the murine fibrosarcoma cell line L929. Because of its high 
TNF sensitivity, this cell line has been used in many labora- 
tories as a prototype in the study of TNF cytotoxicity. 
However, it should be stressed that some TNF-induced 
signaling mechanisms eem to be cell type-dependent. 
2. Necrosis versus apoptosis 
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ence of metabolic inhibitors, TNF can induce necrotic or 
apoptotic cell death [12,13]. Necrosis is characterized by 
cell swelling, destruction of cell organelles and cell lysis. 
In apoptosis, the cell shrinks, apoptotic bodies are 
formed, and in most cases specific internucleosomal 
DNA fragmentation is observed. It is still unclear 
whether DNA fragmentation is the cause or simply the 
result of TNF-induced cell death. TNF-treated L929 
cells die of necrosis [ 13,141, although internucleosomal 
DNA fragmentation can be observed at late time points 
after TNF addition [15]. 
3. TNF receptors 
The trimeric TNF exerts its effect by binding to and 
clustering specific high-affinity receptors which are pres- 
ent on the plasma membrane of almost all cell lines, the 
number varying between 100 and 10,000 [16]. Although 
it is a prerequisite, the presence of TNF receptors is not 
sufficient in order to be sensitive to TNF cytotoxicity 
[17]. So far, two TNF receptors with a molecular mass 
of 55 kDa (~55) and 75 kDa (~75) have been identified 
and cloned (reviewed in [3,18]). The two receptor types 
consist of an extracellular domain which binds TNF and 
is 28% homologous, a transmembrane region, and an 
intracellular part which is totally different and does not 
contain any recognizable structure which can be associ- 
ated with a particular function. The remarkable absence 
of homology between the intracellular egions of the two 
TNF receptors suggests that they are involved in differ- 
ent functions or signal-transducing pathways. L929 cells 
contain about 350 ~55 and 750 ~75 receptors [19]. Stim- 
ulation of L929 cells (transfected with human ~55 and 
~75 receptors) with agonistic antibodies or TNF mutants 
specific for human ~55 or ~75 receptors has shown that 
TNF cytotoxicity in this cell line, as in most other cell 
lines, is mainly or only induced by the ~55 receptor. 
Occasionally, a more important role for ~75 in TNF 
cytotoxicity in some particular cell lines was proposed 
[20,21], but this has been contradicted [22]. Although ~75 
is not essential for cytolytic activity, it may play a helping 
role. Tartaglia and coworkers [23] proposed a model in 
which the ~75 ‘presents’ TNF to the ~55 receptor in 
non-lymphoid cells and at low TNF doses. In addition 
to TNF cytotoxicity, the ~55 receptor also seems to me- 
diate many other activities of TNF, such as cytokine 
induction, fibroblast proliferation and prostaglandin 
synthesis [24]. So far, a direct role for ~75 has only been 
demonstrated in T lymphocytes and derived cell lines, 
where TNF induces cytokines and/or cell proliferation 
[25,26]. After binding of TNF to its receptors, the 
complex is rapidly internalized and degraded [27]. 
Whether internalization and degradation are necessary 
in order to induce cytotoxicity is still under debate 
[28,29]. The receptor is not recycled and new protein 
synthesis is required to maintain cell surface receptor 
number [30]. 
4. Post-receptor mechanisms 
As mentioned in the previous section, structural and 
functional heterogeneity in TNF receptors, each linked 
to distinct intracellular messenger systems, cannot fully 
explain variations in TNF response. Response heteroge- 
neity is certainly also brought about by a diversification 
of post-receptor signal-transducing pathways. 
TNF cytotoxicity does not require RNA or protein 
synthesis [31]. On the contrary, in the presence of the 
transcription inhibitor actinomycin D or the translation 
inhibitor cycloheximide, the cytotoxic activity of TNF is 
considerably increased and most TNF-resistant cells be- 
come even TNF-sensitive. This suggests the presence 
and/or induction by TNF of so-called ‘TNF resistance 
proteins’. Indeed, some TNF-induced proteins have been 
identified which can partially inhibit TNF cytotoxicity 
when overexpressed in particular cell lines [32-351. The 
observation that at least two phenotypically different 
sublines can be derived from L929 cells, suggests the 
existence of different resistance mechanisms within one 
single cell line [36]. Interestingly, transfection of TNF- 
sensitive L929 cells with the TNF gene under a constitu- 
tive promoter induces TNF resistance by downregula- 
tion of the receptors; how the latter effect is brought 
about, is still under investigation [19,37]. 
One can distinguish early, fairly fast (within minutes), 
and late (within hours) biochemical effects of TNF. In 
contrast to some other hormones and cytokines, TNF 
has to be continuously present with the cells for several 
hours in order to induce a maximal cytotoxic effect. This 
fact makes it difficult to determine the exact role of early 
and late TNF-induced effects in the signaling to cell 
death. Although the early effects might be involved in 
priming the cells, they cannot fully explain TNF cytotox- 
icity, as most of them are already reduced to background 
levels within less than 1 h. 
4.1. G protein activation 
It has been reported by several aboratories that per- 
tussis toxin inhibits TNF cytotoxicity [38-40]. Pertussis 
toxin ADP-ribosylates the G proteins G,, Gi, and G,, 
and uncouples them from receptors. Branellec and co- 
workers [41] found that pertussis toxin-catalyzed ADP 
ribosylation of G proteins is considerably decreased in 
TNF-treated cell membranes from MCF-7 cells. 
Furthermore, Imamura et al. [40] reported that TNF 
promotes guanine nucleotide binding to the membranes 
of L929 and HL-60 cells. This increase in GTP binding 
is associated with a parallel increase in GTPase ac- 
tivity, which is inhibited by pertussis toxin pretreat- 
ment. Such reports suggest that a pertussis toxin- 
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Fig. 1. TNF-activated protein kinases and phosphatases. TNF treatment of cells leads to early stimulation of several kinases. It should be mentioned 
that not every kinase is activated in the same cell line; for example, the activation of mitogen-activated protein (MAP) kinase, S6-kinase, p-casein 
kinase and heat-shock protein (hsp) 27 kinase has been demonstrated in L929 cells. Moreover, for most of these kinases a direct role in TNF 
cytotoxicity seems unlikely. Instead, TNF sensitization observed with the general protein kinase inhibitor staurosporine (STS) suggests that a sofar 
unidentified protein kinase, which might be TNF-activated, counteracts the TNF signal. In addition, the protective effect of vanadate on TNF 
cytotoxicity for L929 cells suggests a role for a TNF-activated phosphatase in the signaling to cell death. PKC, protein kinase C; EGF, epidermal 
growth factor. 
sensitive G protein might be involved in TNF cytotox- 
icity. Although receptors coupled to G proteins usually 
consist of a seven-transmembrane domain structure [42], 
it has been reported that such a configuration is not 
universal. Indeed, the insulin-like growth factor II recep- 
tor, containing a single transmembrane domain, has 
been demonstrated to couple directly to Gi2 in a manner 
similar to that of conventional G protein-coupled recep- 
tors [43]. 
4.2. NF-KB activation 
TNF binding leads rapidly, i.e. within minutes, to acti- 
vation of the transcription factor NF-KB, which means 
that the heterodimer p55-~65 is released from IKB and 
can move from the cytoplasm to the nucleus, where it 
binds to specific loci on the DNA. However, there is no 
evidence that NF-KB activation is involved in TNF 
cytotoxicity, although the signaling mechanisms leading 
to TNF cytotoxicity and NF-KB activation seem to 
partially overlap. For example, protease inhibitors 
have been shown to inhibit both TNF cytotoxicity and 
NF-KB activation [44,45]. However, it is not known 
whether the relevant protease system is the same in both 
types of biological effects. On the other hand, some phos- 
pholipase inhibitors only protect against TNF cytotox- 
icity [46]. 
4.3. Protein phosphorylation 
In some cells rapid phosphorylation occurs after TNF 
treatment [47,48] (Fig. 1). In L929 cells as well as in some 
other cell lines, a rapid activation of several cytosolic 
Ser/Thr protein kinases, with a maximum already at 
10 min post TNF treatment, has been demonstrated. 
Among these are casein kinase-2 as well as the two ex- 
tracellular signal-regulated kinases erk- 1 and erk-2, also 
known as MAP2 kinases [49,50]. These kinases are 
thought to play an important role in the phosphorylation 
cascades initiated by growth factors [51]. Activation of 
these kinases might be essential for priming the cells to 
TNF cytotoxicity, but their activation lacks the specific- 
ity needed to explain the unique property of TNF to 
cause tumor cell cytotoxicity. Nevertheless, an essential 
role for protein phosphorylation/dephosphorylation i  
TNF cytotoxicity is suggested by the remarkable synergy 
between TNF and staurosporine 1521. The latter is a 
potent inhibitor of many protein kinases, suggesting that 
a protein phosphorylation step is counteracting the TNF 
signal (Fig. 1). This is further suggested by the observa- 
tion that in L929 cells and in other cell lines, the tyrosine 
phosphatase inhibitor vanadate can inhibit TNF cyto- 
toxicity ([53]; our own unpublished results). The nature 
of the kinase(s) and phosphatase(s) involved is still not 
clear. However, experiments with protein kinase inhib- 
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Fig. 2. TNF-induced lipid hydrolysis and formation of second messengers. TNF-induced clustering of TNF receptors leads to activation of four 
different phospholipases. Phospholipase (PL) A, hydrolyses phospholipids (PL) with the formation of lysophospholipids (LPL) and arachidonic acid 
(AA). The latter can be further metabolized to prostaglandins, leukotrienes and thromboxanes. PLC-mediated hydrolysis of either phosphati- 
dylcholine (PC) or phosphatidylinositol4,Sdiphosphate (PIP,) leads to the formation of the protein kinase C activator diacylglycerol (DAG) on the 
one hand, and of phosphoryl choline (P-Chol) or the Ca”-mobilizing agent inositol triphosphate (IP,), respectively, on the other hand. The latter 
is converted to inositol (I) by a number of inositol phosphate phosphatases, ome of which are inhibited by Li’ ions. PLD-mediated hydrolysis of 
PC results in the formation of phosphatidic acid, which can be converted to cytidine diphosphate (CDP)-DAG, which reacts with I, leading to the 
re-synthesis of PIP,. Finally, sphingomyelinase (SMase) converts sphingomyelin (SM) to P-Chol and the second messenger ceramide. 
itors other than staurosporine have shown that TNF 
sensitization by the latter agent cannot be explained on 
the basis of inhibition of any of the major protein kinases 
known [52]. 
4.4. Phospholipase activation 
Several inhibitors of phospholipase A, (PLA,) reduce 
TNF cytotoxicity in L929 cells and in most other tumor 
cell lines studied. The observation that TNF induces the 
release, after 2 h treatment, of arachidonic acid in TNF- 
sensitive, but not in TNF-resistant L929 cells, further 
supports a role for PLA, [39,54,55] (Fig. 2). Recently, 
Hayakawa et al. [56] showed that a particular TNF- 
resistant subline of L929 has decreased PLA, activity; 
more interestingly, they could reinduce TNF sensitivity 
in this cell line by transfection with the gene coding for 
a recently identified, high-molecular mass, cytosolic, ara- 
chidonic acid-specific PLA,. However, a decreased PLAz 
activity does not seem to be a general mechanism of 
reduced TNF cytotoxicity, as other TNF-resistant L929 
sublines could be derived which did not display these 
characteristics ([56]; our own unpublished results). Meta- 
bolites of arachidonic acid are not involved in TNF cyto- 
toxicity, since several inhibitors of arachidonic acid 
metabolization do not affect TNF cytotoxicity [39]. 
Moreover, there is no reason to believe that arachidonic 
acid itself plays a role in TNF-induced cell lysis, as re- 
lease of the fatty acid occurs equally well by serum treat- 
ment of the cells [55]. The question how PLA, is involved 
in TNF cytotoxicity remains unanswered. Possibly, lyso- 
phospholipids, formed as a result of PLA, activity, are 
cytotoxic for the cells. PLA, activity can be regulated by 
lipocortins. However, TNF has no effect on the level or 
phosphorylation of these proteins [57]. Recently, it has 
been shown that phosphorylation and gene expression of 
the high-molecular mass cytosolic arachidonic acid-spe- 
cific PLA, are increased by TNF treatment of HeLa cells 
[58]. However, in the latter cell line, TNF only induces 
a clear arachidonic acid release in the presence of Ca2+ 
ionophore. Moreover, the observation that phosphoryl- 
ation and activation of this PLAz can be inhibited by 
staurosporine [59], while the latter drug drastically in- 
creases TNF cytotoxicity [52], makes a direct role for this 
particular PLA, in TNF cytotoxicity rather unlikely. 
In addition to PLA,, we have also provided evidence 
for a role of phospholipase C (PLC) activation and inos- 
itol lipid hydrolysis in TNF cytotoxicity (Fig. 2). This is 
based on the finding that a remarkable synergy between 
TNF and lithium ions can be observed in L929 and in 
some other cell lines [60]. One of the better known effects 
of Li’ is the inhibition of two different inositol phosphate 
phosphatases [61]. In agreement with this, we found that 
in L929 cells treated with TNF in the presence of lithium 
ions, inositol mono-, di- and triphosphates as well as 
CDP-diacylglycerol accumulated to appreciable levels 
within 2 h after TNF treatment [62]. TNF-resistant cells 
or cells which are not sensitive to the TNF-sensitizing 
effect of LiCl did not reveal an accumulation of inositol 
phosphates upon treatment with a combination of TNF 
and LiCl, suggesting a role for TNF-induced inositol 
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Fig. 3. Production of superoxide radicals by the mitochondrial respiratory chain. Succinate and NADH are oxidized by succinate dehydrogenase 
and NADH dehydrogenase, respectively. The two electrons (e-) are then passed on to ubiquinone (UQ). From LJQ, e- pass through different 
cytochromes (cyt). Finally, reduced cytochrome c is re-oxidized by the multi-enzyme complex cytochrome oxidase. For every four e- taken in by 
this complex, one oxygen molecule becomes fully reduced to two molecules of water. 1 to 5% of oxygen leaks from this pathway, mainly at the UQ 
site, and undergoes tepwise univalent reduction. The one electron reduction of molecular oxygen generates the superoxide radical (0; ‘). This can 
subsequently be reduced to hydrogen peroxide (H,O,), most commonly in a dismutation reaction catalyzed by superoxide dismutase (SOD). HzOz 
can be directly detoxified to water by a catalase or peroxidase-catalyzed reduction. Alternatively, H,02 can be reduced, usually in an iron-catalyzed 
reaction, to the hydroxyl radical (OH’), which can react with almost every type of organic substrate (S) in living cells. By the use of specific 
mitochondrial inhibitors we found that interference of the electron transport at the NADH and succinate dehydrogenase l vel markedly protected 
the cells against TNF. On the other hand, electron transport inhibition behind the ubiquinone region potentiated TNF cytotoxicity. These results 
suggest hat oxidative events generated in the mitochondria, and not inhibition of energy-coupled processes, are crucial in TNF-induced cytotoxicity. 
lipid hydrolysis in TNF cytotoxicity. The mechanism by 
which an accumulation of inositol phosphates enhances 
TNF cytotoxicity is still unknown. Although a role of 
Ca” ions in TNF-induced cytotoxicity is somewhat con- 
troversial [63,64], it seems quite possible that an inositol 
triphosphate-induced Ca” release from intracellular 
stores enhances the biochemical reactions leading to cell 
death. This is further suggested by the observation that 
several Ca2+-lowering agents partially protect against 
TNF cytotoxicity in L929 cells [62]. Some time ago, 
Schiitze and coworkers [6.5] demonstrated that TNF 
could also rapidly activate a phosphatidylcholine-spe- 
cific PLC in some cell lines, resulting in an increase in 
diacylglycerol levels and protein kinase C activation. 
However, it seems rather unlikely that this activity is 
involved in TNF cytotoxicity, since this particular PLC 
is activated only transiently for 10 min, while TNF cyto- 
toxicity requires the presence of TNF for hours. More- 
over, TNF does not seem to activate this phosphati- 
dylcholine-specific PLC in L929 cells (our own unpub- 
lished observations). 
In addition to PLA, and PLC, also PLD becomes 
activated upon TNF treatment of L929 cells [66] (Fig. 2). 
PLD activity results in the formation of phosphatidic 
acid. Whether the latter plays an essential role in TNF 
cytotoxicity is unknown. Since phosphatidic acid can 
increase cytosolic Ca2+ levels [67], this second messenger 
may further boost the Ca2’ rise induced by inositol tri- 
phosphate formed after PLC activation by TNF. 
TNF treatment of lymphoid cell lines results in the 
rapid activation of a neutral sphingomyelinase, which 
causes sphingomyelin hydrolysis and generation of cer- 
amide [68] (Fig. 2). The elevation in intracellular cer- 
amide levels has been proposed to mediate the effects of 
TNF on cell differentiation. Interestingly, ceramide can 
mimic TNF-induced activation of erk-1 and erk-2 in 
HL-60 cells [69]. Similarly, Dhaibo et al. [70] found that 
ceramide also mimics the growth-inhibitory effect of 
TNF on Jurkat cells, supporting a role for sphingomye- 
lin hydrolysis in the growth-inhibitory effect of TNF on 
these cells. We did not observe an effect of several cer- 
amide analogues on TNF cytotoxicity for L929 cells, nor 
did we find a TNF-induced increase in ceramide forma- 
tion in these cells. These results make a general involve- 
ment of the sphingomyelin pathway in TNF cytotoxicity 
rather unlikely. 
4.5. Mitochondria and oxygen radical production 
Matthews and colleagues [71] were the first to report 
that sensitive cells treated with TNF show abnormalities 
in their mitochondria: they looked swollen and had fewer 
cristae. Recently, we and others published evidence that 
TNF-induced events interfere with the normal electron 
flow in the mitochondria [72-741 (Fig. 3). Moreover, 
when L929 cells are cultured for a long time in ethidium 
bromide or chloramphenicol, it becomes possible to se- 
lect clones which have lost functional mitochondria and 
which lack mitochondrial DNA. These cell clones have 
become virtually resistant o TNF-induced cytotoxicity, 
further suggesting a role of mitochondria in TNF cyto- 
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Fig. 4. Working hypothesis for TNF-induced signaling leading to cell death in L929 cells (see text for further details). AA, arachidonic acid; Chol, 
choline; DAG, diacylglycerol; ER, endoplasmic reticulum; G, G protein; IcB, inhibitor KB; IP,, inositol triphosphate; LYSOPL, lysophospholipids; 
MIT, mitochondria; Mn-SOD, manganous uperoxide dismutase; NF-rcB, nuclear factor KB; 0; ‘, superoxide radical; PA, phosphatidic acid; PAI-2, 
plasminogen activator inhibitor type 2; PLA,, phospholipase A,; PLC, phosphohpase C; PLD, phospholipase D; PK, protein kinase; PM, plasma 
membrane. 
toxicity [75]. Of interest, the TNF-induced cytokine 
synthesis (e.g. interleukin-6) is also largely abolished 
in these cells, strongly suggesting that the pathways 
leading to cytotoxicity and gene induction are at least 
partially overlapping. Another finding implicating mito- 
chondrial involvement in response to TNF was the 
observation that TNF induces, at least in some cells, 
the mitochondrial protein manganese superoxide dis- 
mutase, which confers resistance to TNF [32]. The above 
observations led to the hypothesis that reactive oxygen 
formation in the mitochondria plays an essential role in 
TNF cytotoxicity (Fig. 3). This is further supported by 
the observations that TNF cytotoxicity does not occur 
under anaerobic conditions and that there is direct evi- 
dence for lipid peroxidation based on the formation of 
malonyldialdehyde production [71]. If free radicals are 
involved in TNF-mediated killing, it may be predicted 
that free radical scavengers would inhibit cytolysis. The 
data indicate that some scavengers do indeed protect, but 
some others do not [39,76]. The finding that iron chela- 
tors inhibit killing is consistent with a role for TNF- 
induced free radical damage [39,74]. Iron catalyzes the 
Fenton reaction which produces the highly toxic hy- 
droxyl radical from hydrogen peroxide. Direct measure- 
ments of radical production have led to rather controver- 
sial results. A l&fold increase in hydroxyl radical for- 
mation was found in tumorigenic mouse fibroblast L-M 
cells exposed to TNF for 18 h [77]. By the use of lu- 
cigenin-enhanced chemiluminescence Hennet and co- 
workers [78] showed that TNF induced an increase in 
superoxide anion generation. In contrast, we were not 
able to detect an increase in radical production upon 
TNF stimulation of L929 cells, although radicals pro- 
duced after stimulation with menadione were readily de- 
tectable with the method used (V. Goossens et al., in 
preparation). The reason for this discrepancy is still un- 
clear. However, the fact that in contrast to our results 
[14], Hennet et al. [79] also obtained protection with the 
proto-oncogene bcl-2, which is known to prevent apop- 
tosis, suggests that cell line difference might be the expla- 
nation for these divergent results. The absence of a gen- 
eral increase in radicals in our L929 cells is in apparent 
contrast with the protection obtained with some radical 
scavengers and with the TNF resistance observed for 
cells lacking functional mitochondria. A possible expla- 
nation may be based on a redistribution of mitochondria 
after TNF stimulation, resulting in a localized TNF- 
induced increase in radical production. A similar mito- 
chondrial redistribution has already been observed in 
several cell types, for example in phorbol myristate ace- 
tate-activated macrophages [80]. 
Reactive nitrogen intermediates are other types of free 
radicals which are able to inhibit mitochondrial func- 
tions, and which are cytostatic and cytotoxic to tumor 
cells [81]. TNF has recently been shown to induce the 
synthesis of NO synthetase and the production of NO in 
L929 cells [82]. A direct role for reactive nitrogen inter- 
mediates in TNF cytotoxicity is unlikely, since inhibitors 
of NO production and NO scavengers do not protect 
against TNF cytotoxicity [83]. 
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4.6. Are other biochemical pathways involved? 
Inhibitors of serine-type proteases protect cells from 
TNF-induced lysis, suggesting that a protease may be 
involved in the cell-killing process [44,84]. In addition, 
ADP ribosylation of particular proteins is observed from 
4 h on after exposure to TNF. Furthermore, inhibitors 
of ADP ribosylation also prevent TNF-mediated cyto- 
toxicity [85], suggesting an important role of ADP ri- 
bosylation either in signal transduction or in mediating 
toxic reactions. 
5. Discussion: a model of TNF-induced cytotoxicity 
Considerable effort has been devoted to clarify the 
post-receptor mechanisms of TNF. However, the availa- 
ble data are difficult to interpret, since they have been 
obtained on a variety of cells which respond differently 
to TNF. In this review, we focused on those biochemical 
pathways which are thought to be implicated in the proc- 
ess of TNF-mediated cytotoxicity. Fig. 4 summarizes the 
biochemical pathways which are possibly involved in the 
induction of TNF cytotoxicity in L929 cells. Upon bind- 
ing to its cell surface receptors, TNF initiates competing 
processes: transcription of protective genes vs. a pro- 
gramme of self-destruction. Receptor clustering activates 
protein kinases and phospholipases, possibly through 
the activation of a pertussis toxin-sensitive G protein. 
This results in the formation of arachidonic acid, inositol 
phosphates, diacylglycerol, phosphatidic acid and deriv- 
atives. These mediators in some way, either directly or 
through the release of other second messengers, activate 
new pathways (including mitochondrial radical produc- 
tion) which finally result in cell death. 
Although the above described signaling pathways fit 
in a model of TNF cytotoxicity, there is strong evidence 
that at least some of these signaling pathways are also 
involved in the induction of other TNF-induced biologi- 
cal responses. For example, modulation of the inositol 
metabolism by LiCl not only increases TNF cytotoxicity, 
but also TNF-induced mitogenesis (our own unpub- 
lished results), TNF-induced inflammation [86] and 
TNF-induced gene activation [87]. Moreover, several 
other growth factors and hormones which induce totally 
different activities, also use pathways which at least 
partially overlap those stimulated by TNF. The main 
question therefore is: how is selectivity obtained? Fur- 
thermore, many other critical questions regarding TNF 
cytotoxicity remain to be answered. Among them are: 
what is the role of the different TNF receptors? Is there 
a role for receptor phosphorylation? Are TNF receptors 
directly associated with signaling molecules? What deter- 
mines the outcome of the competing metabolic proc- 
essT? How are the phospholipases activated? Is there a 
role’,for mitochondrial radical production? Are the early, 
transient, effects of TNF on, for example, protein phos- 
15 
phorylation involved in the signaling process leading to 
cell death? With the availability of specific antibodies 
against the two TNF receptors and several signaling 
molecules, as well as the corresponding cloned genes, it 
is now possible to investigate in detail questions related 
to the functional role of the two receptor proteins and 
their link to the intracellular signaling machinery. Fur- 
ther studies will hopefully yield a cohesive picture of the 
intracellular signal transduction network which links 
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